Apr 28, 2015

Adynxx to present at the American Pain Society Annual Scientific Meeting on May 14th, 2015

SAN FRANCISCO, CALIF., April 28, 2015 – Don Manning, chief medical officer, will present a poster at the 34th Annual Scientific Meeting of the American Pain Society from Wednesday, May 13th to Friday, May 15th in Palm Springs, CA. Dr. Manning will present an poster entitled “AYX2 transcription factor decoy produces a long-term resolution of chronic pain following a single intrathecal injection by inhibiting the triumvirate of KLF6, 9 and 15 transcription factors” during an author attended ession from 3:45pm – 5:15pm on Thursday, May 14th.

 About Adynxx

Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

Adynxx’s lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at thetime of surgery. Adynxx has completed the initial Phase 2 clinical trial of AYX1 and is currently enrolling a second, dose-ranging Phase 2 clinical trial. Additional compounds targeting a range of intractable neuropathic and inflammatory pain syndromes are in the pre-clinical stage.